EUVIMEDEUVIMED entdecken
Crossref

Quantitative Analysis of Branaplam (LMI070) in Human Plasma by LC‐MS/MS in Support of Clinical Trial in Infant Patients With Spinal Muscular Atrophy (SMA)

Yunlin Fu iD, Wenkui Li iD, Franck Picard

Biomedical Chromatography · 2026-12 · 40 (12)

DOI: 10.1002/bmc.70656 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 10.11.2026. Verfasst von Yunlin Fu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetic Sciences - Drug Disposition, Novartis Biomedical Research, One Health Plaza, East Hanover, New Jersey, USA. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Muscular Atrophy, Spinal, Thiazoles. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

When in vivo bridging between conventional venous sampling and patient centric capillary sampling (or microsampling) is not feasible for pharmacokinetic (PK) assessment, collection of small volumes of venous plasma is a viable approach to support regulated clinical trial in pediatric populations. A sensitive LC‐MS/MS method was developed and validated for the quantification of LMI070, a drug candidate for the treatment of spinal muscular atrophy (SMA), in plasma samples collected from a first‐in‐human, first‐in‐patient trial in infant patients. The method has a dynamic range of 0.200–200 ng/mL using 20‐μL sample volume. The accuracy and precision of the method along with other validation parameters met the predefined requirements. The method was successfully implemented in timely analysis of plasma samples to support PK/PD and other assessments of the trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryLiquid Chromatography-Mass SpectrometryMuscular Atrophy, SpinalThiazolesHumansInfantReproducibility of ResultsLinear ModelsLimit of Detection

Stichwörter der Autor:innen

LC‐MS/MSbranaplam (LMI070)clinical sample analysispediatric trialsspinal muscular atrophy (SMA)

Substanzen

Thiazoles

Autor:innen und Institutionen

  • Pharmacokinetic Sciences - Drug Disposition, Novartis Biomedical Research, One Health Plaza, East Hanover, New Jersey, USA.
  • Pharmacokinetic Sciences - Drug Disposition, Novartis Biomedical Research, Basel, Switzerland.

ORCID-Profile: Yunlin Fu, Wenkui Li

Zitieren

APA

Fu, Y., Li, W., & Picard, F. (2026). Quantitative Analysis of Branaplam (LMI070) in Human Plasma by LC‐MS/MS in Support of Clinical Trial in Infant Patients With Spinal Muscular Atrophy (SMA). Biomedical Chromatography, 40(12). https://doi.org/10.1002/bmc.70656

Vancouver

Fu Y, Li W, Picard F. Quantitative Analysis of Branaplam (LMI070) in Human Plasma by LC‐MS/MS in Support of Clinical Trial in Infant Patients With Spinal Muscular Atrophy (SMA). Biomedical Chromatography. 2026;40(12). doi:10.1002/bmc.70656

BibTeX
@article{Fu2026,
  author = {Fu, Yunlin and Li, Wenkui and Picard, Franck},
  title = {Quantitative Analysis of Branaplam (LMI070) in Human Plasma by LC‐MS/MS in Support of Clinical Trial in Infant Patients With Spinal Muscular Atrophy (SMA)},
  journal = {Biomedical Chromatography},
  year = {2026},
  volume = {40},
  number = {12},
  doi = {10.1002/bmc.70656}
}
Kostenlos starten →